SY 003
Alternative Names: SY-003Latest Information Update: 28 Jun 2022
At a glance
- Originator Yabao Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in China
- 01 May 2018 Preclinical trials in Cancer in China (unspecified route), before May 2018 (Yabao Pharmaceuticals pipeline, May 2018)